BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $140 from $135 and keeps a Buy rating on the shares. The company’s Q1 sales beat was driven primarily by a record Zio AT quarter, with continued share gains following a disruption in a competitor’s MCT business in Q4 and contribution from new account openings, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating
- iRhythm price target lowered to $139 from $152 at Canaccord
- Irhythm Technologies: Strong Q1 2025 Performance and Raised Price Target Reinforce Buy Rating
- Strong Commercial Momentum and Strategic Partnerships Drive Buy Rating for Irhythm Technologies
- Wells upgrades iRhythm to Overweight on strong business trends